RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Semaglutide (administered by PDS290 pen-injector) for Obesity

The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor mental health, and decreased life expectancy.

Official registry: https://clinicaltrials.gov/study/NCT07872904 · Signe Torekov · enrollment listed as 400

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Family Care, Standard Care, or Semaglutide (administered by PDS290 pen-injector). The registry lists allocation as randomized. The number of adults and children living with obesity is increasing worldwide.

They plan to enroll about 400 people at Copenhagen. Taking part typically means taking a study drug (or dummy pill), following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

FutureShape Family: A Randomised Controlled Trial of an Enhanced Family Care Intervention Targeting Intergenerational Obesity

Interventions: Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)

Primary outcome (registry wording): Change in body fat percentage

Who it is for (from inclusion criteria)

Ages 5 Years to any
Family living in the same household with at least one Index Parent and one Index Child living with overweight/obesity (see below)
Permanent residency in Denmark and able to speak Danish at a level to understand trial requirements
Living with obesity (body-mass index (BMI) ≥30 kg/m2)
Biological, adoptive parent, or legal guardian of the Index child
Resides with the Index child at least 50% of the time
Index parent(s) must be in possession of a smartphone and able to use an app-based solution
A maximum of two Index Parents per family can participate in the trial

Who the registry excludes

Known serious chronic conditions, including type 1 or 2 diabetes
Known medical conditions that hinder physical activity to a significant degree
Treatment for cancer at screening other than oestrogen antagonist therapy or non-melanoma skin cancer
Known severe psychiatric disease, a history of major depressive episodes, or other serious psychiatric disorders
Known diagnosis or treatment for an eating disorder within the last 6 months
Known medical conditions or use of medication significantly affecting growth (Index Child) or causing clinically significant weight gain or weight loss (Index Parent(s) or Index Child) within the last 6 months before screening
Bariatric surgery and weight-related surgeries (e.g., gastric bypass) within the last two years

Public study contact (from the registry)

Study Team

+4593565828

FutureShape@sund.ku.dk

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

University of Copenhagen, Department of Biomedical Sciences — Copenhagen, Denmark (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07872904 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07872904?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07872904?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary